Australia Group Urges Early-Warning System For Problem Drugs
This article was originally published in PharmAsia News
The Australian Commission on Safety and Quality in Health Care is calling for a federal law to require agencies to cross-check for possible lethal side effects of new drugs. The group said the Pharmaceutical Benefits Scheme and Medicare hold huge amounts of information on illnesses and deaths attributed to medication problems. Even with that information, the nation has no system for early recognition of adverse- event patterns. The health and safety commission also said high-risk groups such as diabetics would benefit the most from advance knowledge of adverse events if patient details were linked to problem medications. (Click here for more
You may also be interested in...
The EU’s massive economic stimulus package, Next Generation EU, includes a wide-ranging health program that aims to make health systems more resilient to future threats by supporting the development and manufacture of affordable new medicines and vaccines as well as measures to prevent drug shortages.
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.